By Maverick Ventures
We are so excited to welcome Jéssica Leão to the Maverick Ventures team.
Jéssica first joined us as an intern last summer, where she was an instrumental player in sourcing projects and working on multiple deals simultaneously, and we are thrilled to have her join us full time.
Jéssica has a deep background in tech with experience as both an operator and investor. Her experience includes investing in pre-seed and seed businesses as Managing Partner at Dorm Room Fund, a student-run VC fund backed by First Round Capital, as well as Founder and General Partner at The…
By Ambar Bhattacharyya
Congratulations to Rachel Haurwitz, Jennifer Doudna, and the entire Caribou (NASDAQ: CRBU) team on today’s public debut! This incredible milestone marks the pinnacle of a decade of scientific innovation and next-generation technology.
Founded by pioneers in CRISPR genome editing, Caribou has fueled the development of next-generation immune cell therapies for the treatment of cancer. For nearly a decade, the company has developed proprietary technology to build a pipeline of wholly-owned allogeneic immune cell therapies for oncology. CB-010, Caribou’s leading program, is an anti-CD19 CAR-T that is currently in a phase 1 trial in B-cell non-Hodgkin lymphoma.
By Ambar Bhattacharyya and Prateesh Maheshwari
We are proud to share our continued investment in HumanFirst (formerly Elektra Labs), leading its $12M Series A along with Lux Capital, Threshold Ventures, Arkitekt Ventures, Boost VC, SV Angel, Village Global, and other angel investors.
Since first leading the seed round in 2019, we have been blown away by the growth and traction of the company and its Atlas platform. Atlas launched in 2019 to ensure safe, effective, and personalized adoption of connected technologies in real-world settings. Since launch, 22 out of the top 25 pharmaceutical companies have used the platform to evaluate…
By David Singer, Ambar Bhattacharyya, Matt Kinsella, and Prateesh Maheshwari
We are excited to announce that we recently closed the third fund cycle of Maverick Ventures, with over $600M in committed capital. This enables us to keep doing what we love to do — support our existing portfolio companies and invest in new, passionate entrepreneurs working in the technology and healthcare fields. Our evergreen fund structure allows us to invest in companies from inception through maturity.
By Prateesh Maheshwari
We’re thrilled to announce our newest investment in KUDO, a cloud-based video conferencing platform with real-time multilingual interpretation.
As the pandemic has made video conferencing ubiquitous, KUDO’s platform has emerged as a key tool for multilingual online meetings and a vital resource for international organizations, governments, and global companies. Demand for KUDO’s services has grown exponentially in the past year, and we’re excited to see the company continue to expand its presence at the forefront of the changing future of work. …
By Ambar Bhattacharyya
We would like to congratulate the team at Cityblock Health, who has just recently announced a $192 million Series C funding. We’re proud of all the hard work the team has continually put in, helping the much-needed communities access quality and affordable care.
COVID-19 has dramatically heightened the need for comprehensive health care and Cityblock has quickly stepped up to the plate to meet people where they are needed the most. By partnering with community-based organizations and health plans to deliver medical care, behavioral health, and social services, Cityblock has transformed the lives of over 70,000 members…
By Matt Kinsella
We are excited to announce our latest investment in Cylera, a leader in the healthcare IoT cybersecurity market.
Medical devices are increasingly connected to hospital networks, with an average of 15–20+ devices per hospital room. This maximizes operational efficiency but unfortunately increases the risk for cyberattacks on patients and healthcare organizations. There seemingly is a new ransomware attack on a hospital every day. Cylera’s cybersecurity platform continuously finds new, existing and unknown assets/devices, provides risk analysis, and detects threats (known and unknown) for critical medical devices such as ventilators, infusion pumps, imaging devices and laboratory equipment. …
By David Singer
We would like to congratulate the Coupang team on their NYSE debut, taking the next step in their mission to set a new global standard for e-commerce companies. We’re proud to have led Coupang’s Series D funding in 2011. Since that time, we have learned a tremendous amount about leadership and the benefits of being obsessively focused on the customer from Bom Kim and his team.
Bom has compounded Coupang’s growth through an unwavering commitment to exceptional service inside of a prescient vision as to what the future of e-commerce will be. We’re proud to have…
We want to congratulate the Seer team on their IPO, the next step on their journey to build an important new company in the proteomics field, enabling scientists and clinicians to ask questions about biological functions in ways that have never been possible before. To learn more about this exciting new technology and the suite of products being developed and commercialized, please visit www.seer.bio.
The views expressed herein are solely the views of the author(s) and are not necessarily the views of Maverick Capital, Ltd. or any of its affiliates. They are not intended to provide, and should not be relied upon for, investment advice.
We would like to congratulate Galecto Biotech on their recent IPO announcement (GLTO). We are so thrilled for the team in reaching this exciting milestone. Reflecting back on our initial investment, Galecto checked a couple of “firsts” for Maverick Ventures.
Back in Fall 2018, before Covid-19 and our current norm of Zoom-only meetings, we met the Galecto team entirely virtually and performed all of our diligence from afar using email, calls, and of course, Zoom. It wasn’t until post-investment that we met face-to-face in Copenhagen. While this may not seem like much of a stretch in today’s world of Zoom-only…